U.S. Court in Massachusetts Allows Regeneron’s Recoupment Counterclaims Against States in FCA Litigation
- March 06, 2026
Eleven states waived their sovereign immunity by suing Regeneron Pharmaceuticals, Inc. for allegedly causing their Medicaid programs to overpay for the company’s age-related macular degeneration treatment Eylea, a federal court in Massachusetts held March 2. The ruling allows Regeneron to assert counterclaims against the states alleging the company overpaid rebates for Eylea to their Medicaid programs.
ARTICLE TAGS
You must be logged in to access this content.